6127507	
500310	
\$40.00	
Ī	

FORM PTO-1595	U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office
	ll ll
Y RECORDANCE OF THE	ORM COVER SHEET IS ONLY
PATENT	Attorney Docket No : 056365-5006-US01
To the Commissioner for Patents	ATTN: BUX ASSIGNMENT
Please record the attached original documents or copy there	Name and address of receiving party(ies):
1. Name of conveying party(ies):	Z. Hallo W
Paul J. Santerre	Name: Interface Biologica Inc.
Additional names of conveying party(ies) attached?	Internal Address:
	Street Address: 200 Front Street, Suite 3004
-	City Toronto, Ontario
3. Nature of convoyance:	
⊠ Assignπieut	Country: Canada
☐ Merger ☐ Security Agreement ☐ Change of Name	Additional manue(s) & address(es) attached?
Other Execution Date: September 28, 2004	☐ Yes ⊠ Nu
4. New Application number(s) or patent number(s): If this document is being filed together with a new application. A. Patent Application No.(s) B. Patent No.(s): 6,127,507	ation the execution date of the application is:
Additional numbers attached: TYes No	
 Name and address of party to whom correspondence concerning document should be mailed: 	6. Total number of applications and patents involved: 1
Name: Paul N. Kokulis	7. Total fee (37 C.F.R. §3.41): <u>\$40.00</u> Enclosed Authorized to be charged to Doposit Account 50-0310
Internal Address: Morgan, Lowis & Bockius LLP Customer No. 09629	S. Deposit Account No. 50-0310 (Attach duplicate page if paying by deposit account)
Street Address: 1111 Pennsylvania Ave., N.W. City: Washington State: D.C. Zip: 20004	
	information is true and correct and any attached copy is a true
Paul N. Kokulis Name of Person Signing Total	The Date: October 20, 2004 I number of pages including cover sheet, attachments and documents: 3
1 Utal	

PATENT REEL: 015259 FRAME: 0464

PAGE 03/04

985-015-9270 g/2004 22:31

PATENT ASSIGNMENT

WHEREAS Dr. Paul Santerre, a citizen of Canada residing at 83 Whitburn Street, Whithy, Ontario, Canada (hereinafter referred to as the "Assignor") has invented certain new and useful improvements in "Fluoreligomer surface modifiers for polymers and articles made therefrom", which is subject to one or more patents on applications, identified as:

Patent Office	Application No./	Patent No./
-	Filing Date	issue Date
PCT	PCT/CA96/00524**	
	July 31, 1996	
Australia	66093/96	711425
	July 31, 1996	October 14, 1999
Canada	2228505	
-	July 31, 1996	
Europe	96925626.2	U842207*
- mral-	July 31, 1996	September 3, 2003
New Zealand	313583	313583
74044 2000-0-0-0	July 31, 1996	May 18, 1999
US	09/198268	6127507
00	November 24, 1998	October 3, 2000
US -	08/690108**	
-	July 31, 1995	
US	60/001883**	
	August 3, 1995	1. 3 Trimedain Tenlar

^{*} validated in Germany, France, the United Kingdom, Italy, and the Netherlands; Spain was designated in the European Regional Phase but not validated after issuance

WHEREAN Interface Biologics Inc. having a principal place of business at 200 Front Street, Suite 3004, Toronto, Ontario, Canada (herein referred to as "Assignee") is desirous of acquiring the rights as may be held in by Assignor, in, to and under said invention and in, to and under any Letters Patent which may result therefrom.

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that for and in consideration of the sum of CDN\$2.00 to it in hand paid by Assignee to the Assignor, and other good and valuable consideration, the receipt of which is hereby acknowledged, said Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over to Assignee, the entire right, title and interest in and to said invention and said patents and applications and any and all continuations, divisions, renewals and substitutes for said patents and applications, and in, to and under any and all Letters Patent which may be granted on or as a result of said applications and any issue or reissues or extension or reexaminations of any Letters Patent and the right to claim priority based on the filing date of these applications under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and the right to apply in all countries in the name of the Assignor or the Assignor for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said invention, the

90%_b>2:1080773.1 1040797

REEL: 015259 FRAME: 0465

^{**} abandoned or lapsed

1/20**0**4 22:31 905 815-9270

- 2 -

all countries in the name of the Assignor or the Assignee for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said invention, the same to be held and enjoyed by the Assignee as fully and entirely as the same could have been same to be held and enjoyed by the Assignor if the sale, assignment and transfer not be made.

Executed this 28th day of Sphomles, 2004.

Witness:
Name:

Assignor Paul Santerie

Date: September 28, 2004

Assignee:

Interface Biologics Inc.

By:

MATTE MARK STESSONAN!

UTIGE: DIRECTOR OF BUSINESS DESERBORDED

Date:

Endern/SMM Assignment

ŢŒ<u>ĸ</u>_¥2*2:*\$96**290**4

RECORDED: 10/20/2004 REEL: 015259 FRAME: 0466